Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Catalent U K Swindon Zydis Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner and 1 distinct art unit. The presence of only 1 pending matter indicates a specific or limited engagement with the patent office at this time. Practitioners should focus on the unique requirements of this art unit to ensure the application progresses efficiently through the examination phase.
The busiest examiner for this portfolio is KASSA, TIGABU, who is currently handling 1 pending office action. This single action constitutes the full extent of the company's pending prosecution before the USPTO. Because the busiest examiner pending count is 1 and the total pending office actions is 1, the company's immediate patent outcomes are tied to this specific examiner's review. Practitioners should tailor their approach to the specific standards of the Biotechnology & Pharmaceuticals area as applied by KASSA, TIGABU. Navigating the preferences of this 1 distinct examiner is essential for successful prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.6% | +27.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030541 | STABLE ORAL DISPERSIBLE FORMULATION FOR EPINEPHRINE | KASSA, TIGABU | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030541 | STABLE ORAL DISPERSIBLE FORMULATION FOR EPINEPHRINE | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 44d overdue | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCatalent U K Swindon Zydis Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Tigabu Kassa has the most, with 1 of Catalent U K Swindon Zydis Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.